Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUSP3 | P51452 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21394352 | 1.00 | DUSP3 (0.35) | DUSP3PDK2KDM4EATML3MBTL1 | |
| SCHEMBL21394539 | 1.00 | DUSP3 (0.35) | DUSP3PDK2KDM4EATML3MBTL1 | |
| SCHEMBL21394540 | 1.00 | DUSP3 (0.35) | DUSP3PDK2KDM4EATML3MBTL1 | |
| SCHEMBL21394419 | 0.98 | DUSP3 (0.34) | DUSP3PDK2KDM4EATML3MBTL1 | |
| SCHEMBL21394414 | 0.98 | DUSP3 (0.34) | DUSP3PDK2KDM4EATML3MBTL1 | |
| SCHEMBL21394350 | 0.98 | DUSP3 (0.34) | DUSP3PDK2KDM4EATML3MBTL1 | |
| SCHEMBL21394294 | 0.98 | DUSP3 (0.34) | DUSP3PDK2KDM4EATML3MBTL1 | |
| SCHEMBL21394349 | 0.98 | DUSP3 (0.34) | DUSP3PDK2KDM4EATML3MBTL1 | |
| SCHEMBL21394418 | 0.98 | DUSP3 (0.34) | DUSP3PDK2KDM4EATML3MBTL1 | |
| SCHEMBL21394541 | 0.98 | DUSP3 (0.34) | DUSP3PDK2KDM4EATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11239425-B2 | Organic light emitting device | LG CHEM, LTD. (KR) | 2022-02-01 | — | — | US | disclosed |
| EP-3351536-B1 | ORGANIC LIGHT-EMITTING DEVICE | LG CHEMICAL LTD (KR) | 2021-07-21 | — | — | EP | disclosed |
| US-20190296243-A1 | ORGANIC LIGHT EMITTING DEVICE | LG CHEM, LTD. (KR) | 2019-09-26 | — | — | US | disclosed |
| US-10367149-B2 | Organic light-emitting device | LG CHEM, LTD. (KR) | 2019-07-30 | — | — | US | disclosed |
| EP-3351536-A1 | ORGANIC LIGHT-EMITTING DEVICE | LG Chem, Ltd. (KR) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017074052-A1 | ORGANIC LIGHT-EMITTING DEVICE | 주식회사 엘지화학 | 2017-05-04 | — | — | WO | disclosed |
| US-9203033-B2 | Nitrogen-containing heterocyclic compounds and organic electronic device comprising the same | LG CHEM, LTD. (KR) | 2015-12-01 | — | — | US | disclosed |
| US-9203033-B2 | Nitrogen-containing heterocyclic compounds and organic electronic device comprising the same | LG CHEM, LTD. (KR) | 2015-12-01 | — | — | US | disclosed |
| US-20140209884-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND ORGANIC ELECTRONIC DEVICE COMPRISING THE SAME | LG CHEM LTD. (KR) | 2014-07-31 | — | — | US | disclosed |
| US-20140209884-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND ORGANIC ELECTRONIC DEVICE COMPRISING THE SAME | LG CHEM LTD. (KR) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10367149-B2 | Organic light-emitting device | CRY1, PPOX, CRY2 | DUSP3 4249/4885PDK2 2784/4885KDM4E 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.